Mural Oncology plc(MURA) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress Company remains well positioned to capitalize on the role of cytokines with near- and long-term potential value creation milestones, reiterates guidance on projected cash runway into Q4 2025 On track to report readouts from Mural's lead asset, nemvaleukin alfa, in two late-stage clinical trials in 1H 2025 Presented clinical data from ARTISTRY-3 on less frequent dosing of nemvaleukin at the Am ...